Discover an Easier Way to Monitor CML

Don't wait weeks for CML monitoring results

61% of newly treated patients consider their lives abnormal while they wait for their monitoring results. Only 32% of patients receive their monitoring results within 15 days or less1


Timely CML monitoring results ensure that milestone “warning” responses are rapidly identified and acted upon, potentially avoiding higher patient costs2, and easing anxiety for the patient


Fast, sensitive and standardized measurement of BCR-ABL transcript in less than 3hrs3



1. Patient survey – Cepheid literature D19681
2. Goldberg S et al. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2017 Jul 28;92:1214–1223
3. Package Insert 302-0742 Rev. B GXBCRABL-10

About Cepheid

Based in Sunnyvale, California, Cepheid is a leading molecular diagnostics company dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated molecular diagnostic testing for organisms and genetic-based diseases.

Visit to view our entire portfolio of molecular diagnostic tests and systems.

Download informational brochure

In submitting this form, I agree to be contacted by Cepheid to receive information on products, goods & services, it may include similarly related products, goods, or services from its affiliates. Consent may be withdrawn at any time. For additional information about how we handle your personal data, please review our online privacy policy

Cepheid Logo

Vira Solelh, Maurens-Scopont, 81470 France
+33 563 825 319 |

Copyright © 2020 Cepheid. All Rights Reserved. Privacy Policy